JP2024545695A - Ｅｐ４アンタゴニストの結晶塩形態 - Google Patents

Ｅｐ４アンタゴニストの結晶塩形態 Download PDF

Info

Publication number
JP2024545695A
JP2024545695A JP2024537165A JP2024537165A JP2024545695A JP 2024545695 A JP2024545695 A JP 2024545695A JP 2024537165 A JP2024537165 A JP 2024537165A JP 2024537165 A JP2024537165 A JP 2024537165A JP 2024545695 A JP2024545695 A JP 2024545695A
Authority
JP
Japan
Prior art keywords
compound
free acid
cancer
crystalline free
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545695A5 (enExample
Inventor
ファリド ベナユード，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2024545695A publication Critical patent/JP2024545695A/ja
Publication of JP2024545695A5 publication Critical patent/JP2024545695A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024537165A 2021-12-23 2022-12-22 Ｅｐ４アンタゴニストの結晶塩形態 Pending JP2024545695A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293183P 2021-12-23 2021-12-23
US63/293,183 2021-12-23
PCT/US2022/053842 WO2023122289A1 (en) 2021-12-23 2022-12-22 Crystalline salt form of ep4 antagonist

Publications (2)

Publication Number Publication Date
JP2024545695A true JP2024545695A (ja) 2024-12-10
JP2024545695A5 JP2024545695A5 (enExample) 2025-12-17

Family

ID=85222399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537165A Pending JP2024545695A (ja) 2021-12-23 2022-12-22 Ｅｐ４アンタゴニストの結晶塩形態

Country Status (7)

Country Link
US (1) US20250051285A1 (enExample)
EP (1) EP4452949A1 (enExample)
JP (1) JP2024545695A (enExample)
KR (1) KR20240124927A (enExample)
CN (1) CN118414328A (enExample)
CA (1) CA3242277A1 (enExample)
WO (1) WO2023122289A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061751A1 (en) 2010-09-21 2016-08-31 Eisai R&D Management Co., Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
CA3242277A1 (en) 2023-06-29
WO2023122289A1 (en) 2023-06-29
US20250051285A1 (en) 2025-02-13
CN118414328A (zh) 2024-07-30
KR20240124927A (ko) 2024-08-19
EP4452949A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
US10710987B2 (en) Hydrochloride salt form for EZH2 inhibition
US12152034B2 (en) FGFR inhibitors and methods of making and using the same
AU2009220856B2 (en) Crystal form of phenylamino pyrimidine derivative
TWI540133B (zh) 嘧啶衍生物之製造方法
JP5162236B2 (ja) イミダゾール化合物
WO2018210296A1 (zh) 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
AU2025202624A1 (en) Polymorphic forms of compound and preparation method therefor and application thereof
US20250051285A1 (en) Crystalline salt form of ep4 antagonist
JPWO2019189766A1 (ja) 新規ビアリールアミド誘導体
JP5442711B2 (ja) Ｈｄｌ−コレステロール上昇剤としての２−トリフルオロメチルニコチンアミド誘導体
CN112759546B (zh) 3-(二甲氨基甲基)哌啶-4-醇衍生物及其制备方法和药物用途
HK40109783A (en) Hydrochloride salt form for ezh2 inhibition
CN118459465A (zh) 氘代稠合杂环化合物及其制备方法和药物组合物、结合物及应用
WO2025139868A1 (zh) Trpv3抑制剂及其制备和应用
CN115551842A (zh) 联苯类化合物
WO2021254464A1 (zh) 取代喹唑啉类化合物、其制备方法、药物组合及应用
NZ718201B2 (en) Hydrochloride salt form for ezh2 inhibition
HK1227873A1 (en) Hydrochloride salt form for ezh2 inhibition
HK1227873B (en) Hydrochloride salt form for ezh2 inhibition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251209